Clindamycin phosphate adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Clindamycin phosphate
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Generic name
Class: Lincosamide antibacterial
Also reported as: Clindamycin Phosphate Solution

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 1,891 adverse event reports that name Clindamycin phosphate. In these reports the drug is a suspect or interacting product.

In the same period, 1,577 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 134 reports in the 12 months to June 2026 and 154 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Clindamycin phosphate is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

No update is on record for this page. The record starts when FDA adds the reports of July to September 2026.

In April to June 2026, FDA received 28 reports that name Clindamycin phosphate.
In January to March 2026, FDA received 34.
In April to June 2025, FDA received 34.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 176 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 1,874 of the 1,891 reports (99.1%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 176 terms.

Reaction terms in the reports that name Clindamycin phosphate, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 1,891 reports
Drug ineffectivethe medicine did not work as expected	291	15.4%
Drug hypersensitivityan allergic-type reaction (the term names a medicine)	187	9.9%
Off label useused for a purpose or in a way not on the label	153	8.1%
Rashskin rash	124	6.6%
Condition aggravatedthe condition being treated got worse	72	3.8%
Diarrhoealoose or frequent stools	72	3.8%
Product use in unapproved indicationused for a purpose not on the label	71	3.8%
Painpain, site not specified	70	3.7%
Pruritusitching	70	3.7%
Erythemaskin redness	68	3.6%
Nauseafeeling sick	58	3.1%
Drug ineffective for unapproved indication	50	2.6%
Acute kidney injurysudden loss of kidney function	47	2.5%
Pyrexiafever	47	2.5%
Dyspnoeashortness of breath	43	2.3%
Hidradenitis	41	2.2%
Hypertensionhigh blood pressure	39	2.1%
Malaisegeneral feeling of being unwell	39	2.1%
Urticariahives	37	2%
Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement	35	1.9%
Product quality issuea problem with the product itself	34	1.8%
Abdominal pain upperupper stomach pain	32	1.7%
Treatment failurethe treatment did not work	29	1.5%
Arthralgiajoint pain	28	1.5%
Psoriasispsoriasis, a skin condition	28	1.5%
Rash maculo-papulara rash of flat and raised spots	28	1.5%
Dizzinesslight-headedness or unsteadiness	27	1.4%
Renal failure acute	27	1.4%
Clostridium difficile infection	25	1.3%
Fatiguetiredness	25	1.3%
Acute generalised exanthematous pustulosis	24	1.3%
Hypersensitivityan allergic-type reaction	24	1.3%
Burning sensationa burning feeling	23	1.2%
Cough	21	1.1%
Diabetes mellitusdiabetes	21	1.1%
Drug interactionan interaction between medicines	21	1.1%
Maternal exposure during pregnancythe mother took the medicine during pregnancy	21	1.1%
Scara scar	21	1.1%
Skin lesion	21	1.1%
Anaphylactic reactiona severe, sudden allergic reaction	20	1.1%
Drug eruption	20	1.1%
Abdominal discomfortstomach discomfort	19	1%
Drug intolerancethe medicine was not tolerated	19	1%
Eosinophilia	19	1%
Toxic skin eruption	19	1%
Headachehead pain	18	1%
Left ventricular dysfunction	18	1%
Pulmonary embolisma blood clot in the lung	18	1%
Sleep apnoea syndromepauses in breathing during sleep	18	1%
Toxic epidermal necrolysisa severe skin reaction with peeling	18	1%

Download all 176 terms of Clindamycin phosphate (CSV)

The counts add to more than 1,891 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Same ingredient, other names

Reporters write a brand name or a generic name. Each name has its own page and its own count.

Names of Clindamycin with a page, in the order generic names, brand names, names as reported
Name	Name type	Reports
Clindamycin	Generic name	12,779
Clindamycin hydrochloride	Generic name	1,836
Clindamycin phosphate (this page)	Generic name	1,891
Cleocin	Brand name	651

Sum of the separately reported names: 17,157. A report that names two of these names is in the sum two times. The sum is not the number of reports for the ingredient.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Clindamycin phosphate, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Congenital Anomaly/Birth Defect	Other Serious (Important Medical Events)	Not serious
2004	9	8	0	2	3	0	0	3	1
2005	37	37	6	4	15	3	0	21	0
2006	33	32	7	3	10	0	0	23	1
2007	5	4	0	0	3	0	0	1	1
2008	13	11	2	2	4	0	0	8	2
2009	41	28	2	2	11	1	0	17	13
2010	49	37	8	2	10	2	0	25	12
2011	43	30	4	1	15	1	0	19	13
2012	44	27	1	3	6	1	0	18	17
2013	70	28	2	0	14	0	0	20	42
2014	72	46	4	2	37	1	0	35	26
2015	56	32	6	1	16	2	0	22	24
2016	94	46	8	5	17	0	0	37	48
2017	61	31	5	5	14	2	1	20	30
2018	142	88	9	10	44	0	0	52	54
2019	140	84	12	10	41	3	0	51	56
2020	113	75	10	9	27	1	0	52	38
2021	110	79	17	6	31	1	0	53	31
2022	162	114	13	22	51	2	0	87	48
2023	192	119	10	16	51	3	1	91	73
2024	167	120	12	15	71	10	1	70	47
2025	167	133	10	17	57	4	0	92	34
2026	71	48	1	8	28	1	0	31	23

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Clindamycin phosphate, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Clindamycin phosphate, by the year in which FDA received them
Year	Reports
2004	7
2005	35
2006	37
2007	5
2008	11
2009	28
2010	68
2011	46
2012	49
2013	71
2014	69
2015	62
2016	94
2017	69
2018	153
2019	150
2020	106
2021	116
2022	158
2023	187
2024	152
2025	156
2026	62

Reports that name Clindamycin phosphate, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Clindamycin phosphate
Age	Reports	Share
Under 2	7	0.4%
2 to 11	58	3.1%
12 to 17	61	3.2%
18 to 44	350	18.5%
45 to 64	364	19.2%
65 to 74	228	12.1%
75 and over	198	10.5%
Age not given	625	33.1%

Sex of the patient in the reports that name Clindamycin phosphate
Sex	Reports	Share
Female	1,069	56.5%
Male	589	31.1%
Unknown or not given	233	12.3%

Type of reporter in the reports that name Clindamycin phosphate
Reporter	Reports	Share
Physician	622	32.9%
Pharmacist	169	8.9%
Other health professional	532	28.1%
Lawyer	6	0.3%
Consumer or non-health professional	527	27.9%
Not given	35	1.9%

Age and sex are as the report gives them. The reporter is the primary source in the report. 45.4% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Clindamycin phosphate record
Indication as recorded (MedDRA)	Reports	Share
Acne	119	6.3%
Hidradenitis	55	2.9%
Cellulitis	37	2%
Infection	35	1.9%
Antibiotic therapy	25	1.3%
Antibiotic prophylaxis	20	1.1%

The reporter fills in the indication, and the field is often empty. Each share is of all 1,891 reports.

Drugs in the same reports

Other drugs that the reports of Clindamycin phosphate name, in any role, in order of name
Drug	Reports that name the two
Amoxicillin	42
Ciprofloxacin	75
Doxycycline	61
Doxycycline hyclate	46
Levofloxacin	42
Meropenem	62
Metformin	44
Metronidazole	68
Prednisone	69
Vancomycin	52

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Clindamycin same ingredient
Clindamycin hydrochloride same ingredient
Cleocin same ingredient
Clindamycin palmitate hydrochloride same class
Clindamycin hcl same class
Clioquinol next in the A to Z list
Clioquinol Flumethasone next in the A to Z list
Clobazam next in the A to Z list
Clobetasol next in the A to Z list
Climara Pro next in the A to Z list
Clobetasol propionate next in the A to Z list
Climara next in the A to Z list

These links are for navigation. No count selected them. The class page lists each drug of the class.

Official pages

DailyMed labels for Clindamycin phosphateThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Clindamycin phosphate: adverse event reports that FDA received. https://reportedreactions.com/drug/clindamycin-phosphate/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Clindamycin phosphate as a suspect or interacting product. The 1,577 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Clindamycin phosphate was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Clindamycin phosphate?

No. It is a count of what people reported to FDA: 1,891 reports from January 2004 to June 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Physician (32.9%), other health professional (28.1%) and consumer or non-health professional (27.9%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page